The project E4C uses supercomputers in the search of therapies (small molecule drugs) against SARS-CoV-2.
In particular E4C has a pipeline of phenotypic and target based screens to evaluate the efficacy of repurposed, commercial and de-novo designed compounds.
E4C invites organisations to submit proposals for screening of their compounds for efficacy profiling on the E4C Biology platforms.
The minimum requirements for providing physical compounds are:
Full criteria and conditions are defined in the “Drug-Box” submission portal on the E4C website.